Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax - CNRS - Centre national de la recherche scientifique
Journal Articles Frontiers in Oncology Year : 2023

Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax

Abstract

The S184 residue of Bax is the target of several protein kinases regulating cell fate, including AKT. It is well-established that, in cellulo , the substitution of S184 by a non-phosphorylatable residue stimulates both the mitochondrial localization of Bax, cytochrome c release, and apoptosis. However, in in vitro experiments, substituted mutants did not exhibit any increase in their binding capacity to isolated mitochondria or liposomes. Despite exhibiting a significant increase of the 6A7 epitope exposure, substituted mutants remain limited in their ability to form large oligomers, suggesting that they high capacity to promote apoptosis in cells was more related to a high content than to an increased ability to form large pores in the outer mitochondrial membranes.
Fichier principal
Vignette du fichier
2023 Simonyan et al Fron Oncol.pdf (3.76 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04255643 , version 1 (24-10-2023)

Identifiers

Cite

Lilit Simonyan, Mathilde Gonin, James Hanks, Jordan Friedlein, Kevin Dutrec, et al.. Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax. Frontiers in Oncology, 2023, 12, ⟨10.3389/fonc.2022.1068994⟩. ⟨hal-04255643⟩

Collections

CNRS INC-CNRS
17 View
5 Download

Altmetric

Share

More